BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 953 filers reported holding BAXTER INTL INC in Q1 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $316,000 | -96.5% | 3,614 | -97.4% | 0.02% | -96.5% |
| Q4 2017 | $9,049,000 | +2145.4% | 139,995 | +2001.7% | 0.72% | +2146.9% |
| Q2 2017 | $403,000 | +15.5% | 6,661 | -15.5% | 0.03% | +39.1% |
| Q4 2016 | $349,000 | -92.7% | 7,882 | -94.6% | 0.02% | -96.6% |
| Q3 2015 | $4,808,000 | +13.9% | 146,350 | +137.4% | 0.68% | -2.7% |
| Q1 2015 | $4,222,000 | +245.8% | 61,636 | +269.9% | 0.70% | +121.6% |
| Q4 2014 | $1,221,000 | -69.0% | 16,662 | -69.7% | 0.32% | -68.8% |
| Q3 2014 | $3,940,000 | +44.5% | 54,902 | +45.6% | 1.01% | +14.5% |
| Q2 2014 | $2,727,000 | +236.3% | 37,720 | +242.3% | 0.88% | +145.8% |
| Q1 2014 | $811,000 | +5.2% | 11,021 | -0.6% | 0.36% | -32.3% |
| Q4 2013 | $771,000 | -17.0% | 11,087 | -21.6% | 0.53% | -59.2% |
| Q3 2013 | $929,000 | – | 14,146 | – | 1.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 53,850,000 | $2,054,378,000 | 20.84% |
| Smithwood Advisers, L.P. | 1,000,000 | $38,150,000 | 10.54% |
| SECTOR GAMMA AS | 937,600 | $35,769,000 | 9.19% |
| Smithwood Advisers, L.P. | 500,000 | $19,075,000 | 5.27% |
| Veritas Asset Management LLP | 10,592,749 | $404,113,000 | 5.07% |
| York Capital Management Global Advisors, LLC | 7,887,822 | $300,921,000 | 4.47% |
| Iguana Healthcare Management, LLC | 325,000 | $12,399,000 | 4.08% |
| Osher Van de Voorde Investment Management | 174,160 | $6,644,000 | 3.82% |
| PURA VIDA INVESTMENTS, LLC | 200,000 | $7,630,000 | 3.22% |
| Governors Lane LP | 600,000 | $22,890,000 | 3.22% |